Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

What I find most compelling is the broad nature of the growth. While much attention focuses on Lilly's incretin franchise, Mounjaro and Zepbound, the non-incretin portfolio grew 17% YoY ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...